| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2019-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f080cb5a45ed8aa1b9afeab6f6457451
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a58a3af83ff2d5bdfc0889eff143a89f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28ce7010a6e920aaa576457863866f85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74fc89a1a2869ef5dd19926e8196410b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d629dfc7f07348c7ff2b026d81cd4dc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eec0db809a6bebc03100adb1035b340 |
| publicationDate |
2020-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202035442-A |
| titleOfInvention |
Modified antibody fcs and methods of use |
| abstract |
Biological macromolecules have tremendous potential for the treatment of disease of the central nervous system (CNS), however, the presence of the blood brain barrier (BBB) makes achieving a therapeutically relevant antibody concentration extremely challenging. Antibodies with enhanced neutral pH affinity for the neonatal Fc receptor demonstrate improved accumulation in the brain. Variants disclosed herein also enhanced exposure in engineered mouse models. Using an anti-BACE1 antibody, these Fc variants significantly reduced the levels of brain Abeta. |
| priorityDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |